BiotechTube
Home/LineaRx/Beth Jantzen
BJ

Beth Jantzen

Chief Financial Officer (APDN)

LineaRx

Therapeutic Areas

Infectious DiseaseOncologyGenetic DisordersVeterinary Medicine

LineaRx Pipeline

DrugIndicationPhase
LineaDNA for mRNA/IVT TemplatesmRNA Vaccine & Therapeutic ProductionPlatform/Partnership
LineaDNA for DNA VaccinesProphylactic & Therapeutic VaccinationPlatform/Partnership
LineaDNA for Cell & Gene TherapiesViral Vector & Gene Editing Component ProductionPlatform/Partnership
Linea™ IVT SystemHigh-Purity mRNA ProductionPlatform/Product
LineaDNA for Monoclonal AntibodiesAntibody Development & Transient ExpressionPlatform/Partnership
LineaDNA for Personalized MedicinePatient-Specific TherapiesResearch/Platform

Leadership Team at LineaRx

CS
Clay Shorrock
President of LineaRx, Inc., Chief Legal Officer, Exec. Director Business Development (APDN)
View full LineaRx profile